

# How to submit prior authorization requests for medical benefit drugs

For Blue Cross commercial and BCN commercial

Revised May 2025

Follow these steps to submit prior authorization requests when prescribing most drugs covered under the medical benefit for Blue Cross Blue Shield of Michigan and Blue Care Network commercial members.

Note: The information below doesn't apply to oncology medical benefit drugs.

## Michigan prescribers

To submit prior authorization requests electronically:

- 1. Log in to our provider portal (<u>availity.com</u>\*).
- 2. Click Payer Spaces on the menu bar and click the BCBSM and BCN logo.
- 3. Click the Medical/Pharm Drug Benefit Prior Auth (Commercial) tile on the Applications tab.
- 4. In the Medical and Pharmacy Drug PA Portal, click the Authorization menu and select Add New.
- 5. Enter the member's last name, date of birth, subscriber ID and authorization start date.
- 6. Click Search and then select the appropriate member in the member list.
- 7. Complete all required fields and submit the request.

If you're registered for Availity Essentials<sup>™</sup> but aren't able to access it, submit the prior authorization request using the *Medication Authorization Request Form*, or *MARF*, that's on the next page. Fax it to the number on the form.

### Non-Michigan prescribers

When submitting prior authorization requests, prescribers located outside of Michigan should complete the appropriate steps on the <u>Getting Started</u> page on **ereferrals.bcbsm.com**. Look in the *Submit prior authorization requests* section.

If a non-Michigan prescriber is unable to submit a prior authorization request using the instructions on the webpage, submit the request using the *Medication Authorization Request Form*, or *MARF*, that's on the next page. Fax it to the number on the form.

## Information about the Medical and Pharmacy Drug PA Portal

To help you learn how to use the Medical and Pharmacy Drug PA Portal, view a recorded demo by going to Blue Cross and BCN's Provider Training site, searching on *drugs* and launching the *Medical and Pharmacy Drug PA Portal Overview*.

For detailed information about accessing the Provider Training site, see the "Online training" section of the Training Tools page on **ereferrals.bcbsm.com**.

\*Clicking this link means that you're leaving the Blue Cross Blue Shield of Michigan and Blue Care Network website. While we recommend this site, we're not responsible for its content.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal and electronic data interchange services.

#### Blue Cross Blue Shield/Blue Care Network of Michigan Medication Authorization Request Form

#### Rystiggo® (rozanolixizumab-noli) J9333



Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

This form is to be used by participating physicians to obtain coverage for Rystiggo. For <u>commercial members only</u>, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

O.B. Address  agnosis City /State/Zip  ug Name Phone/Fax: P: ( ) - F: ( ) -  use and Quantity NPI  rections Contact Person  te of Service(s) Contact Person Phone / Ext.		PATI	ENT INFORMATION		PHYSICIAN INFORMATION
OB.   Male   Female   Address    agnosis   City/State/Zip    Date and Quantity   NPT    Contact Person   Fr.   F.    Disease STATE INFORMATION    1. Is this request for:   Initiation   Continuation   Date patient started therapy:    2. Please provide the NPI number for the place of administration:    3. Initiation AND Continuation of therapy:    a. Please check the patient's diagnosis:   Generalized myasthenia gravis with anti-acetylcholine receptor (AChR) positivity     Generalized myasthenia gravis with anti-muscle-specific kinase (MuSK) positivity     Other:     B. If anti-acetylcholine receptor (AChR) positive, how was the patient identified? (Please attach any tests confirming diagnosis)     Anti-AChR antibody test   Edrophonium test   Clinical response to oral cholinesterase inhibitors (ex. pyridostigmine)     Repetitive nerve stimulation (RNS)   Single-fiber electromyography (SFEMG)   Other:     C. If anti-muscle-specific kinase (MuSK) positive, how was the patient identified? (Please attach any tests confirming diagnosis)     Anti-MuSK antibody test   Edrophonium test   Clinical response to oral cholinesterase inhibitors (ex. pyridostigmine)     Repetitive nerve stimulation (RNS)   Single-fiber electromyography (SFEMG)   Other:	ıme				Name
City/State/Zip   Phone/Fax: P: ( ) . F: ( ) .	Number				Specialty
yanne   PhoneFax: P. ( ) . F. ( )	O.B.		☐Male ☐Fema	le	Address
sea and Quantity    NP	agnosis				City /State/Zip
se and Quantity  sections  Contact Person  It is this request for:   Initiation   Continuation   Date patient started therapy:    2. Please provide the NPI number for the place of administration:    3. Initiation AND Continuation of therapy:  a. Please check the patient's diagnosis:   Generalized myasthenia gravis with anti-acetylcholine receptor (AChR) positivity      Generalized myasthenia gravis with anti-muscle-specific kinase (MuSK) positivity      Other:      b. If anti-acetylcholine receptor (AChR) positive, how was the patient identified? (Please attach any tests confirming diagnosis)      Anti-AChR antibody test   Edrophonium test   Clinical response to oral cholinesterase inhibitors (ex. pyridostigmine)      Repetitive nerve stimulation (RNS)   Single-fiber electromyography (SFEMG)   Other:      c. If anti-muscle-specific kinase (MuSK) positive, how was the patient identified? (Please attach any tests confirming diagnosis)      Anti-MuSK antibody test   Repetitive nerve stimulation (RNS)   Generalized myasthenia gravis with anti-muscle-specific kinase (MuSK) positive, how was the patient identified? (Please attach any tests confirming diagnosis)      Anti-MuSK antibody test   Repetitive nerve stimulation (RNS)   Generalized please attach any tests confirming diagnosis)      Anti-MuSK antibody test   Repetitive nerve stimulation (RNS)      Single-fiber electromyography (SFEMG)   Other:      d. Does the patient have a history of thymectomy within 3 months, current thymoma, or other neoplasms of the thymus?      Yes, Please specify   No      e. Which medication did the patient trial and fail for at least 12 weeks?      Methotrevate, Date started:   Date ended:      Cyclosporine, Date started:   Date ended:      Cyclosporine, Date started:   Date ended:      Cyclosporine, Date started:   Date ended:      Gate e					Phone/Fax: P: ( ) - F: ( ) -
te of Service(e)    Contact Person   Let of Service(e)   Contact Person Phone / Ext.					NPI
to Service(s)  ti DISEASE STATE INFORMATION  1. Is this request for:					Contact Person
DISEASE STATE INFORMATION					
1. Is this request for:			DIE		Ext.
2. Please provide the NPI number for the place of administration:		oquest for:			
a. Please check the patient's diagnosis:	1. 15 1115 1	equest ior.		iiiuatioii	Date patient started therapy.
a. Please check the patient's diagnosis:  Generalized myasthenia gravis with anti-acetylcholine receptor (AChR) positivity  Generalized myasthenia gravis with anti-muscle-specific kinase (MuSK) positivity  Other:  b. If anti-acetylcholine receptor (AChR) positive, how was the patient identified? (Please attach any tests confirming diagnosis)  Anti-AChR antibody test  Edrophonium test  Clinical response to oral cholinesterase inhibitors (ex. pyridostigmine)  Repetitive nerve stimulation (RNS)  Single-fiber electromyography (SFEMG)  Other:  c. If anti-muscle-specific kinase (MuSK) positive, how was the patient identified? (Please attach any tests confirming diagnosis)  Anti-MuSK antibody test  Repetitive nerve stimulation (RNS)  Single-fiber electromyography (SFEMG)  Other:  d. Does the patient have a history of thymectomy within 3 months, current thymoma, or other neoplasms of the thymus?  No  e. Which medication did the patient trial and fail for at least 12 weeks?  Date ended:  Pyes  No  Comment:  Date ended:  Date ended:  Date ended:  Pyes  No  Comment:  Pyes  No  Pyes	2. Please	provide the NPI r	number for the place of admir	nistration:	
Repetitive nerve stimulation (RNS)   Single-fiber electromyography (SFEMG)   Other:		a. Please ched General Other:	ck the patient's diagnosis: lized myasthenia gravis with	anti-muscle-specific	kinase (MuSK) positivity
Anti-MuSK antibody test					
d. Does the patient have a history of thymectomy within 3 months, current thymoma, or other neoplasms of the thymus?    Yes, Please specify:		Anti-Mu	SK antibody test	☐ Repetitive	e nerve stimulation (RNS)
e. Which medication did the patient trial and fail for at least 12 weeks?    Methotrexate, Date started: Date ended:   Azathioprine, Date started: Date ended:   Cyclosporine, Date started: Date ended:   Cyclophosphamide, Date started: Date ended:   Mycophenolate mofetil, Date started: Date ended:   Tacrolinua, Date started: Date ended:   Other:, Date started: Date ended:   Step patient currently receiving and will continue to receive a standard of care regimen for their diagnosis?   Yes		d. Does the pa	atient have a history of thyme	ectomy within 3 mont	
Methotrexate, Date started: Date ended:					weeks?
Cyclophosphamide, Date started: Date ended:  Mycophenolate mofetil, Date started: Date ended:  Tacrolimus, Date started: Date ended:  Other:, Date started:  Started:, Date ended:  Is the patient currently receiving and will continue to receive a standard of care regimen for their diagnosis?  Yes No Comment:  G. Will the patient be receiving Rystiggo concurrently with other biologic therapies for myasthenia gravis or immunoglobulin therapy?  Yes no Comment:			•		
☐ Cyclophosphamide, Date started:					
Mycophenolate mofetil, Date started: Date ended:     Tacrolimus, Date started: Date ended:     Other: , Date started: Date ended:     Is the patient currently receiving and will continue to receive a standard of care regimen for their diagnosis?     Yes		U Cyclosp	orine, Date started:	Dat	e ended:
Other:, Date started: Date ended: f. Is the patient currently receiving and will continue to receive a standard of care regimen for their diagnosis?   Yes		☐ Cycloph	iosphamide, Date started:		Date ended:
Other:, Date started: Date ended:   f. Is the patient currently receiving and will continue to receive a standard of care regimen for their diagnosis?   Yes		☐ Mycopn	nue Data startad:	L Date ended:	vale ended:
f. Is the patient currently receiving and will continue to receive a standard of care regimen for their diagnosis?  Yes No Comment:  g. Will the patient be receiving Rystiggo concurrently with other biologic therapies for myasthenia gravis or immunoglobulin therapy?  Yes no Comment:  4. Continuation request: Rystiggo start date		Other:	nus, Date starteu.	Date ended. Date star	ted. Date ended:
g. Will the patient be receiving Rystiggo concurrently with other biologic therapies for myasthenia gravis or immunoglobulin therapy?  Yes no Comment:		f. Is the patier	nt currently receiving and will	continue to receive	
		g. Will the pati	ient be receiving Rystiggo co	ncurrently with other	biologic therapies for myasthenia gravis or immunoglobulin therapy?
				ila an thannan with D	
Yes No Comment				ile on therapy with K	ysuggu :
	Please add ar	ny other suppor	ting medical information n	ecessarv for our re	view
Please add any other supporting medical information necessary for our review	Coverage will	not be provided	I if the prescribing physician	's signature and da	te are not reflected on this document.
Please add any other supporting medical information necessary for our review  Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.	☐ Request for e	xpedited review: I ce	ertify that applying the standard rev	riew time frame may seri	ously jeopardize the life or health of the member or the member's ability to regain maxi
Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.  Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain may		ame	F	Physician Signature	Date
Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.  Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain ma function	Step 2:	☐ Form Comp	eletely Filled Out		☐ Concurrent Medical Problems
Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.    Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain ma function    Physician's Name				Mailbox	
Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.    Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain may function   Physician's Name	Step 3: Submit	1-877-325-59		IVIAIIDUX	P.O. Box 312320, Detroit, MI 48231-2320